Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Anbio Biotechnology changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 10 | 5 | −5 |
| Shares | 68.3K | 29.7K | −38.6K (−56.5%) |
| Value | $2.54M | $894.3K | −$1.65M (−64.8%) |
New holders (0)
Institutions that held Anbio Biotechnology at the end of Q4 2025 but not at the end of Q3 2025.
None.
Sold out (5)
Institutions that held Anbio Biotechnology at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Marshall Wace, LLP | 10,443 | $389.0K |
| Millennium Management LLC | 7,080 | $263.7K |
| XTX Topco Ltd | 6,896 | $256.9K |
| HRT Financial LP | 6,013 | $223.0K |
| Bank of America Corp | 21 | $782 |